# NMDA Receptor Modulation for Hyperarousal in PTSD

> **NCT03166501** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 24 (actual)

## Conditions studied

- Depression
- Post Traumatic Stress Disorder

## Interventions

- **DRUG:** Lanicemine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03166501
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-09-01
- **Primary completion:** 2019-11-12
- **Final completion:** 2019-11-14
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2020-08-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03166501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03166501, "NMDA Receptor Modulation for Hyperarousal in PTSD". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03166501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*